Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30111765 | 1.00 | GRM2 (0.44) | GRM2CNR2CYP2C9MARS1HSD11B1 | |
| SCHEMBL24034836 | 0.84 | GRM2 (0.41) | GRM2CNR2CYP2C9HSD11B1SIGMAR1 | |
| SCHEMBL28906201 | 0.77 | ALDH1A1 (0.43) | GRM2CNR2 | |
| SCHEMBL24034890 | 0.70 | DPP4 (0.39) | GRM2SIGMAR1 | |
| SCHEMBL26133685 | 0.68 | HSD11B1 (0.40) | GRM2CNR2HSD11B1 | |
| SCHEMBL26097001 | 0.67 | TP53 (0.46) | GRM2CYP2C9HSD11B1 | |
| SCHEMBL31333003 | 0.66 | GRIA1 (0.37) | GRM2 | |
| SCHEMBL24034845 | 0.66 | HSD11B1 (0.43) | GRM2HSD11B1 | |
| SCHEMBL30111784 | 0.66 | HSD11B1 (0.43) | GRM2HSD11B1 | |
| SCHEMBL2931350 | 0.65 | GABRA5 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | GRM2 64/4885CNR2 255/4885CYP2C9 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.